Link Plus BioTech

LinkPlus BioTech is a clinical-stage biotechnology company dedicated to the discovery and development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer. The company leverages its proprietary Linker-Plus platform to create ADCs with enhanced stability, site-specific conjugation, and optimized drug-to-antibody ratios. Its lead candidate, LP-001, is a Claudin 18.2-targeted ADC currently undergoing clinical evaluation for gastric and pancreatic cancers. LinkPlus BioTech aims to redefine cancer therapy by delivering more effective and safer treatment options through its robust pipeline of next-generation biologics. With research and development centers in both China and the United States, the company is strategically positioned to advance its candidates through global clinical trials.